Mathematical model of oxygen, nutrient, and drug transport in tuberculosis granulomas

PLoS Comput Biol. 2024 Feb 9;20(2):e1011847. doi: 10.1371/journal.pcbi.1011847. eCollection 2024 Feb.

Abstract

Physiological abnormalities in pulmonary granulomas-pathological hallmarks of tuberculosis (TB)-compromise the transport of oxygen, nutrients, and drugs. In prior studies, we demonstrated mathematically and experimentally that hypoxia and necrosis emerge in the granuloma microenvironment (GME) as a direct result of limited oxygen availability. Building on our initial model of avascular oxygen diffusion, here we explore additional aspects of oxygen transport, including the roles of granuloma vasculature, transcapillary transport, plasma dilution, and interstitial convection, followed by cellular metabolism. Approximate analytical solutions are provided for oxygen and glucose concentration, interstitial fluid velocity, interstitial fluid pressure, and the thickness of the convective zone. These predictions are in agreement with prior experimental results from rabbit TB granulomas and from rat carcinoma models, which share similar transport limitations. Additional drug delivery predictions for anti-TB-agents (rifampicin and clofazimine) strikingly match recent spatially-resolved experimental results from a mouse model of TB. Finally, an approach to improve molecular transport in granulomas by modulating interstitial hydraulic conductivity is tested in silico.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Granuloma / pathology
  • Mice
  • Mycobacterium tuberculosis* / metabolism
  • Nutrients
  • Oxygen / metabolism
  • Rabbits
  • Tuberculosis* / drug therapy
  • Tuberculosis* / pathology

Substances

  • Oxygen

Grants and funding

This study was supported in part by grants from the Bill and Melinda Gates foundation (to RKJ), the NIH (F31-HL126449 to MD), and the intramural research program of the NIH NIAID (to LEV and CEB). RKJ’s research is supported by grants from the NIH - R35-CA197743; U01-CA224348; R01-CA259253; R01-CA208205; R01-NS118929; U01CA261842 and Ludwig Cancer Center at Harvard, Nile Albright Research Foundation, National Foundation for Cancer Research and Jane's Trust Foundation. MD’s research is supported by NIH grant K22-CA258410 and R35-GM151041. LX’s research is supported by grants from the NIH – R01-NS126187 and R01-DC020724, Department of Defense, American Cancer Society, and Children’s Tumor Foundation. JWB’s research is supported by R01-CA284603. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.